Company Active LTD

Company profile

Check4Cancer Ltd

Private Cancer Screening Tests & Diagnostics | Check4Cancer

Check4Cancer | Cancer Screening & Diagnostics | Genetic Counselling & Tests | Private Cancer Tests

CRN
08866941
Founded
2014
Age
12

Overview

Legal name
CHECK4CANCER LTD
Region
East of England
Registered address
LOWER COURT 3-4 COPLEY HILL BUSINESS PARK
CAMBRIDGE ROAD
CAMBRIDGE
UNITED KINGDOM
CB22 3GN
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Check4Cancer Ltd
No active corporate controller recorded.

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
58

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

26 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

12 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

30 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzc3MzQxM2FkaXF6a2N4

Published 30 Sep 2024 03:13

12 Sep
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzNTM3OTg4OWFkaXF6a2N4

Published 12 Sep 2024 08:45

29 Jan
2014

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
8 years

Projects

2022 Collaborative R&D Lead participant

Digital skin cancer diagnosis model

1 Oct 2022 to 31 Mar 2024

Awarded
£338,598
Total cost £483,712

Check4Cancer(C4C) is an award-winning cancer screening&diagnosis provider, and the current skin diagnosis pathway is based on consultant-led telemedicine reporting of digital and dermoscopic images taken in a clinic setting. Rates of skin cancer having been rising significantly during the last three decades and, waiting times for assessment of a suspiciou...

Product types

Collaborative R&D